Horizon Pharma plc (NASDAQ:HZNP) : Average target price received by Horizon Pharma plc (NASDAQ:HZNP) is $33.25 with an expected standard deviation of $8.29. The most aggressive target on the stock is $45, whereas the most downbeat target is $24. 8 financial analysts are currently covering the stock.
Other Equity analysts have also commented on the company shares. Goldman Sachs initiates coverage on Horizon Pharma plc (NASDAQ:HZNP).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Goldman Sachs announces the price target of $24 per share. The rating by the firm was issued on June 6, 2016.
Horizon Pharma plc (NASDAQ:HZNP): stock turned positive on Thursday. Though the stock opened at $17.04, the bulls momentum made the stock top out at $17.45 level for the day. The stock recorded a low of $16.91 and closed the trading day at $17.44, in the green by 3.90%. The total traded volume for the day was 3,903,538. The stock had closed at $16.785 in the previous days trading.
The company shares have dropped -49.76% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $39.49 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $16.25 and the 200 Day Moving Average price is recorded at $17.39. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Nohria Virinder, director of Horizon Pharma Plc, had unloaded 25,000 shares at an average price of $17.69 in a transaction dated on June 15, 2016. The total value of the transaction was worth $442,250.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.